Phase 1 Study of BMS-833923 (XL139)
Phase 1
- Conditions
- Cancer
- Registration Number
- JPRN-jRCT2080221644
- Lead Sponsor
- Bristol-Myers K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
Subjects with advanced or metastatic solid tumors refractory to, or relapsed from, standard therapies or for which there is no known effective treatment.
Exclusion Criteria
Subjects with symptomatic brain metastasis or active brain metastasis requiring treatments.
Inability to swallow oral medication.
Uncontrolled or significant cardiovascular disease.
Inadequate bone marrow function.
Inadequate hepatic function.
Inadequate renal function.
Pancreatitis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of Dose Limiting Toxicity (DLT) and observed adverse events.
- Secondary Outcome Measures
Name Time Method The number of subjects experienced DLT.<br>PK parameters (Cmax, Cmin, Tmax, AUC(TAU), T-half,eff, AI).<br>Best overall response.